Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$SLXP Roth Capital Moves To The Sideline On Salix Pharmaceuticals; Cuts PT To $95 http://www.smarteranalyst.com/2014/11/07/roth-capital-moves-to-the-sideline-on-salix-pharmaceuticals-cuts-pt-to-95/
This is another one - less positive.
$SPPI Roth Capital Reiterates Buy On Spectrum Following 3Q14 Results http://www.smarteranalyst.com/2014/11/07/roth-capital-reiterates-buy-on-spectrum-following-3q14-results/
$SRPT Roth Capital Reiterates Buy On Sarepta Therapeutics Following 3Q:14 Update http://www.smarteranalyst.com/2014/11/07/roth-capital-reiterates-buy-on-sarepta-therapeutics-following-3q14-update/
$SRPT Roth Capital Reiterates Buy On Sarepta Therapeutics Following 3Q:14 Update http://www.smarteranalyst.com/2014/11/07/roth-capital-reiterates-buy-on-sarepta-therapeutics-following-3q14-update/
$NVDA Roth Capital Maintains Buy On Nvidia Following Third Quarter Fiscal 2015 Results http://www.smarteranalyst.com/2014/11/07/roth-capital-maintains-buy-on-nvidia-following-third-quarter-fiscal-2015-results/
$NVDA Roth Capital Maintains Buy On Nvidia Following Third Quarter Fiscal 2015 Results http://www.smarteranalyst.com/2014/11/07/roth-capital-maintains-buy-on-nvidia-following-third-quarter-fiscal-2015-results/
$MPO MLV Reaffirms Hold On Shares Of Midstates Petroleum Following 3Q:14 Results http://www.smarteranalyst.com/2014/11/07/mlv-reaffirms-hold-on-shares-of-midstates-petroleum-following-3q14-results/
$REGN Brean Capital Maintains Buy On Regeneron Pharmaceuticals, $390 PT http://www.smarteranalyst.com/2014/11/07/brean-capital-maintains-buy-on-regeneron-pharmaceuticals-shares-sees-3-upside-for-the-stock/
$CPST Roth Capital Remains Positive On Capstone Turbine Despite Weak FQ2 And Disappointing Outlook http://www.smarteranalyst.com/2014/11/07/roth-capital-remains-positive-on-capstone-turbine-despite-weak-fq2-and-disappointing-outlook/
$PSDV MLV Reiterates Buy On pSivida As All Eyes On Iluvien US Launch http://www.smarteranalyst.com/2014/11/07/mlv-reiterates-buy-on-psivida-as-all-eyes-on-iluvien-us-launch/
$TSLA Tesla Motors Quarterly Update; MLV Reiterates Buy http://www.smarteranalyst.com/2014/11/07/tesla-motors-quarterly-update-mlv-reiterates-buy/
$TSLA Tesla Motors Quarterly Update; MLV Reiterates Buy http://www.smarteranalyst.com/2014/11/07/tesla-motors-quarterly-update-mlv-reiterates-buy/
$CYTX Roth Capital Reiterates Buy On Cytori Therapeutics, $3.50 PT http://www.smarteranalyst.com/2014/11/07/roth-capital-reiterates-buy-on-cytori-therapeutics-3-50-pt/
$CYTX Roth Capital Reiterates Buy On Cytori Therapeutics, $3.50 PT http://www.smarteranalyst.com/2014/11/07/roth-capital-reiterates-buy-on-cytori-therapeutics-3-50-pt/
$NES Roth Capital Maintains Buy On Nuverra Environmental, Sees 112% Upside http://www.smarteranalyst.com/2014/11/07/roth-capital-maintains-buy-on-nuverra-environmental-sees-112-upside/
$CLDX Brean Capital Reiterates Buy On Celldex Therapeutics Following 3Q14 Results http://www.smarteranalyst.com/2014/11/07/brean-capital-reiterates-buy-on-celldex-therapeutics-following-3q14-results/
$PSEC MLV Maintains Buy On Prospect Capital, Sees 21% Upside http://www.smarteranalyst.com/2014/11/07/mlv-maintains-buy-on-prospect-capital-sees-21-upside/
$KERX Maxim Group Reaffirms Buy On Keryx Biopharmaceuticals Ahead Of Ferric Citrate Launch http://www.smarteranalyst.com/2014/11/07/maxim-group-reaffirms-buy-on-keryx-biopharmaceuticals-ahead-of-ferric-citrate-launch/
$NKTR Brean Capital Maintains Buy On Nektar Therapeutics Following 3Q14 Results http://www.smarteranalyst.com/2014/11/07/brean-capital-maintains-buy-on-nektar-therapeutics-following-3q14-results/
$SLXP Salix: Containing Our Frustration - Seeing Steep Selloff As A Bit Overdone, Says Brean Capital http://www.smarteranalyst.com/2014/11/07/salix-containing-our-frustration-seeing-steep-selloff-as-a-bit-overdone-says-brean-capital-2/
$SLXP Salix: Containing Our Frustration - Seeing Steep Selloff As A Bit Overdone, Says Brean Capital http://www.smarteranalyst.com/2014/11/07/salix-containing-our-frustration-seeing-steep-selloff-as-a-bit-overdone-says-brean-capital-2/
$VVUS Brean Capital Reiterates Bearish Position On Vivus Shares, But Keeps $4 PT http://www.smarteranalyst.com/2014/11/07/brean-capital-reiterates-bearish-position-on-vivus-shares-but-keeps-4-pt/
$VVUS Brean Capital Reiterates Bearish Position On Vivus Shares, But Keeps $4 PT http://www.smarteranalyst.com/2014/11/07/brean-capital-reiterates-bearish-position-on-vivus-shares-but-keeps-4-pt/
$ECYT Brean Capital Maintains Hold On Endocyte Following 3Q14 Update http://www.smarteranalyst.com/2014/11/07/brean-capital-maintains-hold-on-endocyte-following-3q14-update/
$SNTA Roth Capital Reaffirms Buy On Synta Pharmaceuticals; Sees 844% Upside http://www.smarteranalyst.com/2014/11/06/roth-capital-reaffirms-buy-on-synta-pharmaceuticals-sees-844-upside/
$SNTA Roth Capital Reaffirms Buy On Synta Pharmaceuticals; Sees 844% Upside http://www.smarteranalyst.com/2014/11/06/roth-capital-reaffirms-buy-on-synta-pharmaceuticals-sees-844-upside/
$DSCO Roth Capital Maintains Buy On Discovery Laboratories Following 3Q14 Update http://www.smarteranalyst.com/2014/11/06/roth-capital-maintains-buy-on-discovery-laboratories-following-3q14-update/
$DSCO Roth Capital Maintains Buy On Discovery Laboratories Following 3Q14 Update http://www.smarteranalyst.com/2014/11/06/roth-capital-maintains-buy-on-discovery-laboratories-following-3q14-update/
$ARIA Shares Of Ariad Are Undervalued And Present Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/11/06/shares-of-ariad-are-undervalued-and-present-upside-says-h-c-wainwright/
$AEZS H.C. Wainwright Downgrades Aeterna To Neutral Following CRL From FDA http://www.smarteranalyst.com/2014/11/06/h-c-wainwright-downgrades-aeterna-to-hold-following-crl-from-fda/
$AEZS H.C. Wainwright Downgrades Aeterna To Neutral Following CRL From FDA http://www.smarteranalyst.com/2014/11/06/h-c-wainwright-downgrades-aeterna-to-hold-following-crl-from-fda/
$KERX Roth Capital Reiterates Buy On Keryx Following 3Q14 Results; Keeps $32 PT http://www.smarteranalyst.com/2014/11/06/roth-capital-reiterates-buy-on-keryx-following-3q14-results-keeps-32-pt/
$OXGN UPDATE: MLV Initiates Buy On Oxigene; Sees 172% Upside For The Stock http://www.smarteranalyst.com/2014/11/06/update-mlv-initiates-buy-on-oxigene-sees-172-upside-for-the-stock/
$TGTX Brean Capital Reaffirms Buy On TG Therapeutics Following Publication Of ASH Abstracts http://www.smarteranalyst.com/2014/11/06/brean-capital-reaffirms-buy-on-tg-therapeutics-following-publication-of-ash-abstracts/
$KERX Brean Capital Maintains Buy On Keryx Biopharmaceuticals On The Back Of 3Q14 Update http://www.smarteranalyst.com/2014/11/06/brean-capital-maintains-buy-on-keryx-biopharmaceuticals-on-the-back-of-3q14-update/
$EDAP H.C. Wainwright Remains Positive On EDAP Following FDA's Guidance http://www.smarteranalyst.com/2014/11/06/h-c-wainwright-remains-positive-on-edap-following-fdas-guidance/
$CLDX Oppenheimer Comments On Celldex Therapeutics Following 3Q14 Results http://www.smarteranalyst.com/2014/11/06/oppenheimer-comments-on-celldex-therapeutics-following-3q14-results/
$FEYE Oppenheimer Maintains Perform On FireEye On The Back Of 3Q14 Earnings http://www.smarteranalyst.com/2014/11/06/oppenheimer-maintains-perform-on-fireeye-shares/
$PCLN Oppenheimer Slightly Cuts Priceline Price Target On Cautious Outlook http://bit.ly/1wA3E4B
$PCLN Oppenheimer Slightly Cuts Priceline Price Target On Cautious Outlook http://bit.ly/1wA3E4B